BBOTBridgeBio Oncology Therapeutics Inc.

$820M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$23M

Net Income

-$22M

EPS (Diluted)

$-0.02

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$734,642

Free Cash Flow

-$734,642

Stock-Based Comp.

$57,919

Balance Sheet

Total Assets

$196M

Total Liabilities

$7M

Stockholders' Equity

$188M

Cash & Equivalents

$963,135

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$23M	-$15M	-49.8%
Net Income	-$22M	-$15M	-42.8%

BBOT Q1 2025 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena